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Abstract Clonality testing in T-lymphoproliferations has
technically become relatively easy to perform in routine
laboratories using standardized multiplex polymerase chain
reaction protocols for T-cell receptor (TCR) gene analysis as
developed by the BIOMED-2 Concerted Action BMH4-
CT98-3936. Expertise with clonality diagnostics and knowl-
edge about the biology of TCR gene recombination are
essential for correct interpretation of TCR clonality data.
Several immunobiological and technical pitfalls that should be
taken into account to avoid misinterpretation of data are
addressed in this report. Furthermore, we discuss the need to
integrate the molecular data with those from immunohistol-
ogy, and preferably also flow cytometric immunophenotyp-
ing, for appropriate interpretation. Such an interactive,
multidisciplinary diagnostic model guarantees integration of
available data to reach the most reliable diagnosis.
Keywords TCR . Clonality . Pitfall . GeneScanning .
Lymphoma
Introduction
Cancer cells are the progeny of a single malignantly
transformed cell, and consequently, these cells are clonally
related. Hence, monoclonality is a key feature of malignant
tumor cell populations, which enables discrimination from
oligoclonal or polyclonal, reactive processes. Clonality
assessment is thus an important tool in the diagnosis of
malignant lymphoproliferations, even though clonality does
not always imply malignancy because some reactive
processes contain large clonal lymphocyte populations.
Establishment of the clonal relationship between multiple
lesions at distinct locations or over time is another useful
application in cancer diagnostics. In lymphoid malignan-
cies, clonality detection is relatively straightforward due to
the ample availability of highly polymorphic DNA markers,
i.e., the rearrangements in the genes encoding the antigen
receptors in B and T lymphocytes, the immunoglobulin (Ig)
and T-cell receptor (TCR) genes, respectively [1–4]. During
early lymphoid differentiation, genes encoding the Ig and
TCR molecules are formed by stepwise rearrangement of
variable (V), diversity (D), and joining (J) gene segments.
This process is referred to as V(D)J recombination [3, 4].
During this recombination process, nucleotides are deleted
and randomly inserted at the joining sites, resulting in an
enormous diversity of unique antigen receptors. As Ig/TCR
gene rearrangements occur sequentially in the earliest
stages of lymphoid differentiation, they are present in
almost all immature and mature lymphoid cells [5–7]. Since
lymphomas and leukemias are derived from a single
malignantly transformed lymphoid cell, the tumor cells of
virtually all lymphoid malignancies contain, in principle, an
identical clonal IGH and/or a clonal IGK/IGL rearrange-
ment in B-cell lymphoproliferations and an identical clonal
TCRG and/or clonal TCRB gene rearrangement in T-cell
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lymphoproliferations. Heterogeneity in Ig/TCR rearrange-
ments thus identifies the presence of polyclonally activated
cells, as opposed to identically rearranged Ig or TCR genes
that reflect a monoclonal lymphoid cell population.
In this report, we address several technical and immu-
nobiological pitfalls especially related to TCR clonality and
its detection in lymphoid malignancies.
T-cell clonality testing
In the late 1990s, a European consortium of ~45 laborato-
ries (BIOMED-2 Concerted Action BMH4-CT98-3936)
was initiated with the aim to establish a highly reliable
standard in polymerase chain reaction (PCR)-based clon-
ality testing, for B-cell as well as for T-cell malignancies.
Figure 1a illustrates a schematic diagram of the human
TCRB locus, showing one of the Vβ gene elements from
the Vβ gene segments, 39–47 are qualified as functional
and belong to 23 families. Both Cβ gene segments (Cβ1
and Cβ2) are preceded by a Dβ gene (Dβ1 and Dβ2) and a
Jβ cluster, which comprises six (Jβ1.1–Jβ1.6) and seven
(Jβ2.1–Jβ2.7) functional Jβ segments. A schematic dia-
gram of the human TCRG locus on chromosome band 7p14
is illustrated in Fig. 2a. The TCRG locus contains only nine
Vγ gene segments that have been shown to undergo
rearrangement. The BIOMED-2-approved set of multiplex
TCRB and TCRG PCR tubes, with the position of the
primers, are shown in Figs. 1b and 2b, respectively. In the
BIOMED-2 approach, the issue of false-negativity was
addressed at several levels: (1) design of complete sets of
primers to cover all possible V–J rearrangements; (2)
inclusion of incomplete rearrangements as additional targets
(e.g., Dβ–Jβ); (3) evaluation of multiple targets per sample.
This concept of complementarity of targets was only
feasible for routine testing by designing multiplex PCR
reaction mixtures consisting of multiple primers. The other
challenge was to prevent false-positivity, which was
achieved by introducing standardized, reliable methods for
evaluation of PCR products: heteroduplex analysis [10, 11],
and GeneScan fragment analysis [12, 13] (Fig. 3). Follow-
ing its technical evaluation [14], the multiplex protocol was
successfully applied to different well-defined WHO lym-
phoma entities with unprecedented high frequencies of
malignant cases showing clonality [15–20]. The sensitivity
of the BIOMED-2 multiplex PCR clonality assays has been
evaluated during the primer design and testing phase. The
detection of virtually all TCR gene rearrangements has a
sensitivity of at least 10% [14]. Multiplex PCR-based
clonality testing and assessment by GeneScan and/or
heteroduplex analysis have become a worldwide standard
[21–24]. Technically, TCR clonality testing and assessment
by GeneScan and/or heteroduplex analysis has become
relatively easy to perform. However, knowledge of and
experience with TCR rearrangement analysis and inclusion
of quality checks in the routine diagnostic setting are
essential to avoid misinterpretation of the data.
Following the guideline of the BIOMED-2 group as
presented in a flowchart in Fig. 4, both TCRG and TCRB
gene rearrangements are analyzed simultaneously in the
routine diagnostic setting for T-cell clonality testing
because both targets provide complementary information
[15]. In addition, usage of both targets in parallel (instead of
consecutively) is efficient and fast, since most laboratories
run clonality assays not more than once a week. The
majority of T-cell neoplasms have clonal TCRG and TCRB
rearrangements with clear complementarity of clonality
detection [17], which is one of the advantages of the
BIOMED-2 clonality testing approach. In fact, the detection
of clonal TCRG and clonal TCRB rearrangements in itself is
a confirmation of clonality detection. Only rarely, isolated
clonal TCRG or TCRB rearrangements are seen. A two-step
triage is recommended for testing TCRD rearrangements.
Because of its complexity, the single tube TCRD assay
should not be routinely used in T-cell clonality diagnostics.
TCRD clonality testing is recommended (1) when there is
evidence for a TCR-γδ proliferation through, e.g., flow
cytometry, (2) upon detection of an isolated clonal TCRG
rearrangement, as this may be considered as indirect
evidence for a TCR-γδ proliferation since TCRG is the
second TCR locus after TCRD to undergo gene rearrange-
ments, or (3) when there is a suspicion of an immature
T-cell neoplasm, e.g., in case of TdT-positive lymphoblasts.
Quality parameters for clonality testing
To ascertain reproducible clonality assessment and to avoid
misinterpretation of the data, DNA-quality, controlled DNA-
input and tissue representativity, are essential quality
parameters to be evaluated in the routine diagnostic setting
[25].
Testing the quality of the extracted DNA from the
pathological specimen is an important parameter, particu-
larly when using formalin-fixed and paraffin-embedded
(FFPE) tissues. The quality of the extracted DNA from
FFPE tissues might be poor, such that the TCR gene targets
are not efficiently amplified. DNA quality should therefore
always be checked in a control PCR analysis in which a
range of differently sized PCR products from nonpolymor-
phic genes are amplified [14]. The BIOMED-2 primers are
designed and validated for DNA-clonality analysis from
fresh or fresh frozen tissues. Although the primers have not
been universally accepted for FFPE tissues, many labora-
tories use the BIOMED-2 primers for FFPE samples as
well. Indeed, when extracted DNA from FFPE samples
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shows amplification up to 300 bp of the control gene PCR,
TCR clonality testing using the BIOMED-2 primers for
TCRB and TCRG is very well feasible. These FFPE
samples have a high detection rate of clonality comparable
to that from fresh frozen samples [Section 10 in 14]
(personal observation). However, when the DNA is
fragmented and shows amplification of 200 or even only
100 bp of the BIOMED-2 control gene PCR, the TCRB-
gene targets (due to the amplicon size of 240–285 bp in
tubes A and B, and 170–210 and 285–325 bp in tube C)
may not efficiently be amplified and therefore potentially
yielding false-negative results [Section 10 in 14]. The
TCRB GeneScan profiles from fragmented DNA samples
may thus be difficult to interpret and may give ambiguous
results. Therefore, we do not recommend testing TCRB
gene rearrangement in the case of fragmented DNA
samples. For the cases showing fragmented DNA, the
TCRG-gene target is more useful and reliable as the
multiplex PCRs for TCRG gene rearrangements yield lower
amplicon sizes between 80 and 255 bp. The detection rate
of T-cell clonality using the TCRG gene as target on DNA
from fresh frozen cases still is 89% [17].
Controlled DNA input is also an important quality
parameter because the lack of both monoclonal and
polyclonal signals, or nonreproducible patterns in a given
sample might be explained by too low or too high amount of
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Fig. 1 PCR analysis of TCRB gene rearrangements. a Schematic
diagram of the human TCRB locus on chromosome band 7q34. The
figure is adapted from the international ImMunoGeneTics database [8,
9]. Only one of the rearrangeable nonpolymorphic functional Vβ gene
segments is depicted (in blue). Both Cβ gene segments (Cβ1 and
Cβ2, depicted in green) are preceded by a Dβ gene (Dβ1 and Dβ2,
depicted in pink) and a Jβ cluster, depicted in light blue. b Schematic
diagram of Vβ–Jβ and Dβ–Jβ rearrangements. The 23 Vβ primers,
13 Jβ primers, and two Dβ primers are combined in three tubes: tube
A with 23 Vβ primers and nine Jβ primers, tube B with 23 Vβ
primers and four Jβ primers, and tube C with two Dβ primers and 13
Jβ primers. The Vβ primers cover approximately 90% of all Vβ gene
segments. Adapted from BIOMED-2 report [14]
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target DNA in the sample, the former due to a low number
of T-lymphocytes in the tissue, the latter due to PCR-
inhibiting factors in the extracted DNA. The latter might
particularly occur in FFPE-derived DNA samples that are
obtained by DNA-extraction methods without further puri-
fication. The input of DNA per PCR is important to be
evaluated in order to be sure that sufficient DNA originating
from target T-lymphoid cells is analyzed and thus to confirm
clonality results. In addition, it is important to exclude
pseudo-clonality, which may occur in the case of low input
of target T-lymphoid cells. In general, 100 ng DNA is used
per PCR (50 ul) for DNA samples obtained from snap-
frozen tissues. For FFPE-samples, we recommend a standard
DNA-extraction procedure using an affinity-purification step
to get rid of small (degraded) DNA strands. Because of the
probability of PCR-inhibiting factors in the sample, two
concentrations, 50 and 200 ng DNA per PCR (50 ul), are
used. Adjustment of the DNA input may be necessary when
there is a low percentage (5–10%) of T cells present in the
tissue sample. The DNA input in these cases is maximally
increased to 400 ng/PCR. To quantitate DNA, affinity
purification of DNA followed by spectrophotometrical
DNA-concentration measurement is recommended.
A third important parameter is tissue representativity. The
number of T lymphocytes and the number of suspect
malignant T cells, should be checked by histological
examination of the same tissue material that was used for
DNA extraction (HE staining of the slides directly prior to
and following the DNA extraction slides) by an experienced
hematopathologist and/or supported by flow cytometry data
whenever available.
Furthermore, we advise for any clonality testing to
include not only monoclonal cell lines [14, 26], but also
polyclonal samples such as peripheral blood mononuclear
cells showing the typical polyclonal pattern of TCR gene
products with a heterogeneous junctional size distribution.
Such polyclonal control samples act as control for primer
quality as well. In addition, samples without rearranged Ig/
TCR genes (e.g., the HeLa epithelial cell line) can be
informative to identify nonspecific bands/peaks that are
sometimes found in multiplex assays [14]. These three types
of control samples facilitate the interpretation of patterns in
the clinical samples.
Interpretation of T-cell clonality data: teaching cases
For interpretation of clonality data, especially in difficult
cases, which are the ones that are also difficult for
pathologists, knowledge of and experience with analysis of
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Fig. 2 PCR analysis of TCRG gene rearrangements. a Schematic
diagram of the human TCRG locus on chromosome band 7p14. Only
the rearrangeable Vγ gene segments are depicted in blue (functional
Vγ) or in gray (nonfunctional Vγ). b Schematic diagram of TCRG Vγ-
Jγ rearrangement with four Vγ primers and two Jγ primers, which are
divided over two tubes. Adapted from BIOMED-2 report [14]
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TCR gene rearrangements are required to avoid misinter-
pretation of the data. Molecular biologists, pathologists,
and clinicians should be aware of several technical and
immunobiologic pitfalls that should be considered when
interpreting TCR clonality findings (Table 1, adapted from
Langerak et al., [25]). Specific aspects of the data analysis
will be discussed by demonstration of two illustrative
cases.
Case 1 concerns a skin lesion of a patient suspected for
cutaneous T-cell lymphoma. Two skin biopsies, from the
palm of the hand and from the arm were used for diagnosis.
The histology of the lesion, showing a polymorphous
infiltrate consisting of CD2-positive lymphocytes, is shown
in Fig. 5. For molecular analysis, snap-frozen tissue
biopsies from two sites were used, containing 80% T cells
of which at least 10% were suspected to be malignant
T cells. The quality of the extracted DNA from both biopsies
was fine, showing an amplification up to 400 bp of the
BIOMED-2 control gene PCR (using the 100-, 200-, 300-,
400- amplicons) [16]. The clonality profile of this patient is
presented in Fig. 6. For this patient, we showed that both
skin biopsies from the patient showed identically sized TCR
gene rearrangements, which supports the clonal nature of the
skin lesions.
Case 2 concerns a patient with an atypical T-cell
infiltrate in the cerebellum, shown in Fig. 7. Clonality
assessment was performed to assess whether infiltrated
T cells were clonal, which may fit to a malignant T-cell
process. FFPE tissue, containing 30% of T cells, most of
which were suspected to be malignant, was available for
clonality testing. Amplification of the extracted DNA was
good (400 bp products could be amplified). Due to the
genomic organization of the TCRG locus and the primer
compositions of the BIOMED-2 TCRG multiplex tubes, the
multiple (at least three) “clonal” TCRG peaks observed as
shown in Fig. 8 are consistent with the presence of at least
two dominant T-cell clones (one clone with TCRG biallelic
rearrangements and one with a single TCRG rearrangement)
in a polyclonal background of T cells. The molecular data
support the morphological findings of a suspect lesion in
the cerebellum, which now is classified as a peripheral T-
cell lymphoma.
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Fig. 3 Schematic diagram of heteroduplex analysis and GeneScan
fragment analysis of PCR products from TCR gene rearrangements. a
Rearranged TCR genes (here TCRB rearrangements are shown as
example) show heterogeneous junctional regions (also known as
junctional motifs) that differ in size and nucleotide composition. V, D,
and J germline nucleotides are shown in large capital and randomly
inserted nucleotides in small capital. Junctional heterogeneity can be
exploited to discriminate between polyclonal and monoclonal PCR
products based on differences in size and composition (heteroduplex
analysis) or size only (GeneScan fragment analysis). b In heteroduplex
analysis, PCR products are denatured (5 min, 94°C) and reannealed
(rapid cooling at 4°C for 60 min) [11]. Monoclonal PCR products (in
this example derived from a case of T-cell large granular lymphocyte
leukemia) give rise to homoduplexes, whereas polyclonal PCR
products (derived from an activated T-cell proliferation during viral
infection) mainly form heteroduplexes, resulting in a smear of slow-
migrating fragments. c In GeneScan fragment analysis, fluorochrome-
labeled PCR products are denatured for high-resolution fragment
analysis of the single-stranded fragments. Monoclonal PCR products
of identical size, as in the case of the T-cell leukemia, give rise to a
peak, whereas polyclonal PCR products show a Gaussian size
distribution. Adapted from BIOMED-2 report [14]
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Generation and technical interpretation of GeneScan
clonality profiles
In the clonality profiles of the two cases (Figs. 6 and 8), it
should be noted that the Y-axes are adjusted so that all
histograms appear similar, with the strongest peak near the
top of the histogram. It is clear that some gene rearrange-
ment amplifications are less abundant than others. The
BIOMED-2 group is aware that in the multiplex PCR tubes
primers have different PCR efficiencies. A good example is
the TCRB-tube B, which is less efficient compared to the
other TCRB tubes and therefore will always give weaker
PCR products. Because of the different PCR efficiencies,
every PCR tube should be interpreted individually (using
adjusted Y-axis), making use of the normal Gaussian
distribution seen in polyclonal pattern of the specific target.
A dominant clonal product in a polyclonal background
of cells is seen in some of the targets, like the TCRG-tube
A, which assesses the Vγ1f and Vγ10 rearrangements
(Fig. 6a), and the TCRB-tube C, which assesses the
incomplete DJ joinings of the TCRB locus (Fig. 6b). Precise
measuring peak intensities or area under the peak is not the
way to interpret clonality results. The BIOMED-2 group
argues against strictly quantitative approaches that compare
the size (or area under the peak) of the seemingly dominant
peak with neighboring peaks in PCR reactions with a
significant polyclonal background, simply because the
multiplex PCRs are not strictly quantitative and because
such quantitative approaches are influenced by the size of
the junctional regions of the clonal peaks. Short and long
junctional regions more likely lead to a “clonal” diagnosis
than intermediately sized junctional regions. Therefore, the
different BIOMED-2 multiplex PCRs should not be
interpreted using an exact algorithm and quantitative rules.
For interpretation of the clonality profiles, it is, of course,
evident that the clonal peak should dominate clearly above
the polyclonal background (as illustrated in Fig. 6a for
TCRG-tube A). Instead of using strict quantitative rules,
however, we strongly recommend the use of an “inverse”
approach in which immunohistological information and
preferably also flow cytometric immunophenotyping infor-
mation about the size of the entire lymphocyte population
and the suspect malignant lymphocyte population are used
to interpret the profile and the distribution of the peaks. The
dominant peak in TCRG-tube A (Fig. 6a) may fit to tumor
tissue containing 80% T cells of which at least 10% were
suspected to be malignant. The dominant clonal peak in
tube A would not fit, for example, to a tumor tissue
containing 80% T cells, all of which were suspected to be
malignant. Note that both the multiplex PCRs as well as the
estimation of the total number of T lymphocytes and the
number of suspect malignant cells are not strictly quanti-
tative. However, it is clear that the clonality profile and the
percentage of suspect malignant cells are related, and
therefore, it is important to use the available immune-
histological information on the percentage of T lympho-
cytes and the percentage of suspect malignant T cells for the
final evaluation of the molecular result. We are aware that
some molecular laboratories apply a strictly quantitative
approach for clonality assessment, without consulting the
pathologist for the histopathological information. We argue
against such practical approach because a strictly quantita-
tive approach can easily miss clonal processes or, more
dangerously, can erroneously assess “clonality”. It is better
to use the(immuno)histopathological information, the
knowledge of the PCR target and to apply the multiple
target TCR approach (TCRB and TCRG) and evaluate the
entire profile of gene rearrangements, in order to reach a
correct interpretation of the clonality results.
Repeating the PCR analysis might provide extra infor-
mation. In diagnostic studies in the case of ambiguous
results or in the case of an isolated target, repeated analysis
using the same sample, a second independent DNA
extraction from the same sample and/or a related sample
is necessary to evaluate consistency of results. Note that
ambiguous results (results that are not reproducible or
difficult to interpret) are mostly derived from DNA samples
from FFPE samples. The TCRB-C tube that corresponds to
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Fig. 4 Flow chart for clonality testing for suspected T-cell proliferations.
Both TCRG and TCRB gene rearrangements are analyzed simultaneous-
ly because of complementarity of the targets and, as such, increase the
clonality detection rate. For tissues showing fragmented DNA, testing
the TCRG-gene target is most useful and reliable because of the lower-
length amplicon sizes. Assessment of TCRB is not recommended in the
case of severe fragmentation of DNA samples
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the TCRB-DJ incomplete rearrangements may be such an
example. For this target, a polyclonal sample should show
two Gaussian curves, with a first set of peaks around
180 bp representing the Dβ2 rearrangements and a second
set of peaks around 300 bp representing the Dβ1 rearrange-
ments. The Dβ1 and Dβ2 gene rearrangements can be well
evaluated in cases that show good amplification. However,
in other cases, the quality of DNA samples may be
HE, 250x HE, 800x
CD3,250x CD2, 250x
Fig. 5 Histology of the skin
biopsy, showing underneath the
epidermis a polymorphous infil-
trate consisting of lymphocytes,
eosinophilic granulocytes
admixed with large atypical
cells. A detail of these cells
shows the big nuclei and nucle-
oli and the irregular nuclear
contour. The cells are positive in
the CD2 staining but they lack
CD3
Table 1 Pitfalls in TCR clonality testinga
Pitfall Phenomenon Solution/action
Bands/peaks just outside size range Junctional regions/junctions
outside 5–95% size range interval
Accept as true rearrangement product; in case of doubt, sequence
for confirmation
Undersized bands/peaks Internal deletion in, e.g., V
segment
Potential rearrangement product; confirm by sequencing
Oversized bands/peaks Extended amplification from
downstream J
Potential rearrangement product; confirm by sequencing
Multiple clonal signals Bi-allelic rearrangements; multiple
rearrangements per allele or
biclonality
Consider the number of potential rearrangements per allele and
per locus and judge whether this fits with clonality or biclonality
Lack of clonal signal and lack of
polyclonal Gaussian curve
Few T cells in sample Check T cell presence by histology or flow cytometry
Low DNA input/PCR Check DNA concentration
Poor DNA quality Check DNA quality in control PCR
Selective amplification and
pseudoclonality, due to low level of
specific template
Few T cells in sample Repeat PCR in multiplicates (same tissue, second independent
DNA isolation, and/or related tissue) → compare patterns for
consistency
Oligoclonal T-cell repertoire in PB of
especially elderly individuals
Incomplete immune system, due
to, e.g., immunosenescence
Repeat PCR in multiplicates (same tissue, second independent
DNA isolation, and/or related tissue) → compare patterns for
consistency and compare with primary process
Oligo-/monoclonality in
histologically reactive lesion
Exaggerated immune response
with dominant specificity
Repeat PCR in multiplicates (same tissue, second independent
DNA isolation, and/or related tissue) → compare patterns for
consistency
(Re)evaluate histopathology→ note that large germinal centers in
the tissue may contain dominant T-cell clone(s)
a Adapted from Langerak et al. [25]
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insufficient to amplify the larger Dβ1 products, not
allowing a proper judgment of this PCR because a
potentially clonal target in these cases may remain
undetected. Also, upon diagnostic requests of cutaneous
NHL or skin biopsies with low numbers of T cells, we
strongly recommend analyzing a second, independent tissue
block from a different site whenever available or at least
ask for follow-up of the patient. Repeated analysis of a
related but independent sample is essential to check for
consistency of the pattern.
With respect to expected size ranges of PCR products
that are mentioned in protocols for a given TCR target, it is
important to realize that those represent the 5–95 percen-
tiles of the natural heterogeneity of the junctional region
[14, 27]. Hence, bands or peaks just outside this size range
can be interpreted as true rearrangement products, even
without formal proof via sequencing. When the products
are considerably smaller (undersized) or larger (oversized),
they still can represent true rearrangements, but then
sequencing analysis is warranted for confirmation.
Not all lymphoma cases need to be evaluated for clonality
assessment because most cases can be diagnosed based on
morphology and immunohistology supplemented by translo-
cation detection or cytogenetics. Molecular clonality assess-
ment is generally performed on 10–15% of the lymphoma
cases, the percentage being dependent on the experience of
the hematopathologist. In our setting of clonality diagnostics,
approximately 5% of evaluated cases give problems in the
interpretation of molecular TCR-clonality results. The diffi-
culties in these cases are severe degradation of DNA and,
consequently, greatly decreased PCR efficiencies resulting in
ambiguous results or the interpretation of a small clonal peak
in a high polyclonal background, seen in an isolated target.
For the latter, our strategy is to assess a second, independent
tissue block from a different site whenever available or ask for
follow-up of the patient.
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Fig. 6 TCR clonality profiles from a diagnostic tissue suspicious for
cutaneous T-cell lymphoma. GeneScan results of the Vγ–Jγ TCRG
gene rearrangements using the BIOMED-2 TCRG-tubes A and B (a);
and of the Vβ–Jβ and Dβ–Jβ TCRB gene rearrangements using the
BIOMED-2 TCRB-tubes A, B and C, respectively (b). Shown are the
results of the extracted DNA from the patients’ tissue (case 1) in
duplicate (100 ng input/PCR), a monoclonal control sample (from a T-
cell lymphoma tissue), and a polyclonal control (from a reactive
lesion). TCR clonality analysis of case 1 showed two clonally
rearranged TCRG genes, which fits to biallelic TCRG clonal
rearrangements (a). Also a clonal TCRB-DJ incomplete rearrangement
was detected (b: TCRB tube C). The rearrangement pattern of the
TCRB-tube A shows a peak pattern, which is interpreted as polyclonal
(low signal) (b). The peak at 273 bp is a so-called false peak as
described before [16, Table 25], since this peak is particularly seen in
samples with low numbers of T cells or in samples in which the clonal
TCRB product is seen in one of the other TCRB tubes, which fits with
the current case
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Heteroduplex analysis or GeneScanning
Heteroduplex analysis is another tool to analyze the PCR
products for discrimination between monoclonal lymphoid
cells with identical junctional regions and polyclonal
lymphoid cells with highly diverse junctional regions.
Heteroduplex analysis uses double-stranded PCR products
and takes advantage of the length and composition of the
junctional regions, whereas in GeneScanning, single-
stranded PCR products are separated in a high-resolution
gel or polymer according to their length only (Fig. 3). The
heteroduplex technique is rapid, simple, and cheap and has
a detection limit of 5–10% [10, 11]. The detection limit is
influenced by the frequency of polyclonal lymphocytes
because the formation of many heteroduplexes will also
consume a part of the monoclonal PCR products [11]. Since
heteroduplex analysis separates PCR products on the basis
of junctional diversity in addition to PCR product size, it is
particularly useful in the analysis of loci with restricted
junctional diversity like that for the TCRG-gene rearrange-
ments. For the TCRB-gene rearrangements, heteroduplex
analysis is particularly useful for the TCRB PCR tubes A
and C (the TCRB VDJ and the incomplete DJ rearrange-
ments, respectively) and slightly less for tube B (the other
set of TCRB VDJ gene rearrangements) because this
multiplex PCR is less efficient compared to the other
TCRB tubes. For this reason, the TCRB PCR tube B will
always give weaker PCR products, which can less easily be
detected using heteroduplex analysis because this approach
is less sensitive compared to GeneScanning. GeneScanning
is rapid and relatively simple, but needs expensive
equipment. GeneScanning is generally more sensitive than
heteroduplex analysis and can reach sensitivities of 1–5%
of clonal lymphoid cells. We prefer the use of GeneScan-
ning because of its sensitivity. In addition, the precise
determination of the size of the PCR product can potentially
be used for nonquantitative monitoring of the clonal
proliferation during follow-up of the patient.
Multiple clonal rearrangements
Knowledge of the TCR loci, immunobiology, and the
pitfalls of the multiplex approach are needed for proper
interpretation of multiple clonal PCR products from one of
the TCR gene targets.
In the TCRB locus, the J gene segments of the two Jβ
clusters have relatively small intergenic distances (a few
hundred basepairs). Consequently, multiple clonal products
may arise by amplification from a downstream J gene
segment, resulting in “oversized” peaks/bands. Sometimes,
this leads to two differently sized PCR products within the
same reaction mixture because of efficient primer annealing
to both the rearranged and the neighboring downstream Jβ
segment (Fig. 9) [27]. Due to the composition of the
BIOMED-2 TCRB multiplex tubes with two V–J reaction
mixtures harboring mutually exclusive sets of Jβ primers,
the situation can look even more complex. In particular
cases, the same Vβ–Jβ rearrangement can be identified
with both mixtures, with the second mixture giving rise to
an “oversized” product because the neighboring down-
HE, 250x HE, 800x
CD3,250x CD3,800x
Fig. 7 Histology of the brain
biopsy, showing a mainly lym-
phoid infiltrate with a mixture of
lymphocytes, including some
larger atypical ones that are CD3
positive
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Fig. 8 TCR clonality profiles from a diagnostic tissue from the
cerebellum which is suspicious of a malignant lesion. GeneScan
results of the Vγ−Jγ TCRG gene rearrangements using the BIOMED-
2 TCRG-tubes A and B (a and c) and of the Vβ–Jβ and Dβ–Jβ TCRB
gene rearrangements using the BIOMED-2 TCRB-tubes A, B, and C,
respectively (b). Shown are the results of the extracted DNA from the
patients’ tissue (case 2) in duplicate (50 and 200 ng input/PCR), with
the arrows indicating the suspect clonal peaks, a monoclonal control
sample (from a T-cell lymphoma tissue) and a polyclonal control
(from a reactive lesion). Clonality analysis of the TCRG gene
rearrangements of case 2 demonstrated suspect clonal peaks in a
polyclonal background of T-cells (a). The interpretation of these
ambiguous clonality profiles was initially difficult. Polyclonal TCRB
rearrangements were observed in this case (b). The clonality profiles
of 50 and 200 ng input of tube C are slightly different, but in both
concentrations, many PCR products are amplified, without dominance
of a particular peak, and so these are considered polyclonal. Note that
the higher amplicon products of the Dβ1 rearrangements amplify most
efficiently in the tube with 50 ng DNA input. Also, TCRD rearrange-
ments were polyclonal (not shown). From the cerebellum lesion, a
second independent and representative tissue block was available,
which showed the presence of a reproducible profile of the TCRG
rearrangement profile (c). The profiles from both biopsies provide
evidence for the presence of multiple dominant T-cell clones
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stream Jβ segment is recognized by the corresponding
primer in the second mixture.
A complex interpretation pitfall concerns the question
whether detection of multiple clonal signals is equivalent to
biclonality. Although biclonal malignancies do occur, first,
several immunobiological and technical explanations for
multiple clonal signals should be considered. Since lym-
phocytes carry two chromosomes, biallelic rearrangements
are more common than biclonality. Second, J segment
clusters such as in the TCRB locus (but also in the IGH,
IGK loci) might give rise to additional “clonal” signals
caused by differently sized PCR products derived from the
same rearrangement. Third, the TCRB locus has a more
complex configuration in that two rearrangements can
occur simultaneously on the same allele, mounting up to a
total of four rearrangements per T-cell clone: a V–Jβ1 or
Dβ1–Jβ1 rearrangement can be followed by a Dβ2–Jβ2
rearrangement on the very same allele [28]. Taken together,
all these phenomena illustrate that, in the case of multiple
clonal signals, biclonality is more of an exception to the rule.
Clonality interpretation should also be performed in the
context of immunobiology. A well-known pitfall concerns
the detection of oligoclonality or even (low level) mono-
clonality of T lymphocytes under certain immunobiologic
conditions [29–35]. Detection of an oligoclonal T-cell
repertoire in elderly individuals should be considered as a
potential sign of an involuting immune system due to aging
of the system (immunosenescence) [36]. Repeated analysis
using the same sample, a second independent DNA
extraction form the same sample and/or a related sample
need to be evaluated for consistency of the results. In true
reactive lesions, oligoclonality or even monoclonality may
reflect an exaggerated immune response with a dominant
immunospecificity. Apart from repeated molecular analysis,
a careful combined (re)evaluation of the clinical, histopath-
ologic, and molecular findings is needed to correctly
interpret oligo-/monoclonality results.
Interactive interpretation model
Knowledge about technical and immunobiological pitfalls
of TCR rearrangement analysis is of utmost importance, but
it does not suffice in all cases. For appropriate interpretation
of the molecular data, it is essential to combine these data
with data from immunohistology and preferably also with
the results from flow cytometric immunophenotyping. Such
an interactive interpretation model, with regular contacts
between clinical molecular biologists, pathologists, hema-
tologists, and immunologists guarantees integration of all
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Fig. 9 Two differently sized
PCR products arising from the
same TCRB rearrangement.
Schematic representation of the
TCRB locus. Shown is an ana-
plastic large cell lymphoma
(ALCL) sample (case 2005-082)
in which the Vβ22–Jβ2.3 rear-
rangement is amplified with the
Jβ2.3 primer from BIOMED-2
TCRB mixture B, while the
same rearrangement is also am-
plified as an “oversized” product
with the Jβ2.4 primer in the
same mixture B. Adapted from
Langerak et al. [25]
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available data to reach the most reliable diagnosis.
Especially, the percentage of suspect malignant lympho-
cytes and the percentages of normal (reactive) B and
T lymphocytes, as available from histopathology and/or
flow cytometry, are important parameters to be considered
for estimating the relevance of the TCR clonality findings.
Thus, the finding of weak clonal signals (in one or more
targets) in a background of polyclonal signals is hardly
compatible with a large suspect cell population, and hence,
such TCR findings should be interpreted with caution. On
the other hand, absence of both monoclonal and polyclonal
TCRG patterns in a sample showing a large T-cell infiltrate
is not compatible and should lead to further analysis of
other TCR targets before definitive conclusions can be
drawn. Finally, the interpretation of clonality can also be
dependent on the clinical presentation. Regular discussions
of cases in multidisciplinary patient meetings should avoid
the aforementioned misinterpretations.
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